Arseni, L., Sigismondo, G., Yazdanparast, H., Hermansen, J. U., Mack, N., Ohl, S., . . . Seiffert, M. Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL. Nature Portfolio.
Chicago Style (17th ed.) CitationArseni, Lavinia, et al. Longitudinal Omics Data and Preclinical Treatment Suggest the Proteasome Inhibitor Carfilzomib as Therapy for Ibrutinib-resistant CLL. Nature Portfolio.
MLA (9th ed.) CitationArseni, Lavinia, et al. Longitudinal Omics Data and Preclinical Treatment Suggest the Proteasome Inhibitor Carfilzomib as Therapy for Ibrutinib-resistant CLL. Nature Portfolio.
Warning: These citations may not always be 100% accurate.